Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Conte

Showing results (221-230 of 225) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 225 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
Pageof 23

Showing results (221-230 of 225) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 225 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2018
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerG N Hortobagyi, S M Stemmer, H A Burris, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
Pageof 23